Route of Administration:
Remicade is a Anti-TNF drug manufactured by Janssen and administered via the Intravenous route of administration. The J Code: J1745 is aligned to the drug Remicade.
Remicade is a prescription medication that works by affecting a certain protein in the body's immune system that causes inflammation. This protein is called the TNF-Alpha protein and has been identified as being involved in multiple inflammatory and auto-immune diseases. Remicade is administered via an intravenous infusion. As of 2023, there are multiple biosimilar drugs for Remicade. These include Inflectra (Q5103), Renflexis (Q5104), and Avsola (Q5121). Johnson and Johnson manufactures Remicade and offers patient financial support and assistance. Information about this program can be found at https://www.jjpaf.org/medications/